Population pharmacokinetics of vancomycin in post-operative neurosurgical patients

doi:10.12092/j.issn.1009-2501.2018.11.009

Abstract

Abstract:

AIM: To establish the population pharmacokinetic model of vancomycin in post-operative neurosurgical patients and to provide information for precision medicine. METHODS: A total of 56 neurosurgical patients with external ventricular drainage were enrolled in this study. Vancomycin was intravenously administered into the patients and blood and cerebrospinal fluid samples were obtained at the scheduled time. Nonlinear mixed-effects modeling method was applied to develop population pharmacokinetic model. Goodness-of-fit, bootstrap and visual predictive check were employed to test the final model.RESULTS:Three-compartmental model (central, peripheral and cerebrospinal fluid compartments) was applied to describe the vancomycin model. The cerebrospinal fluid cell count could significantly affect the clearance between central and cerebrospinal fluid compartments (Qcsf), and the positive relationship was observed between the drainage amount and clearance of cerebrospinal fluid compartment (CLcsf). The estimated values of the model were similar to the median of bootstrap, and they are included in the 95% confidence interval. Bootstrap and visual predictive check demonstrated the stability and performance of the proposed population model. CONCLUSION: The proposed final model can be used to guide clinicians with vancomycin dosing in this specific patient population.

Key words: vancomycin, neurosurgical patients, population pharmacokinetics, cerebrospinal fluid, therapeutic drug monitoring

CLC Number:

R969.1

DING Zhirong, CAI Xiaozhen, ZENG Haiwen, LIN Tianlai. Population pharmacokinetics of vancomycin in post-operative neurosurgical patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1252-1257.

[1]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[2]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[3]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[4]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[5]	HE Jie, LIU Dongxue, ZHONG Lingjun, SHAO Hua, HU Linlin. Establishment of a limited sampling strategy to estimate micafungin exposure in critically ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1264-1271.
[6]	LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan. Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
[7]	LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian. Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
[8]	FU Xiangjun, HUANG Li, GUO Li, LIN Liangmo. Application of AUC/MIC as the therapeutic drug monitoring target of vancomycin in patients with severe infections of multi drug resistant gram positive bacteria [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 775-781.
[9]	PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646.
[10]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[11]	ZHANG Siliang, HU Linlin, SHAO Hua, CHEN Xijing. Research progress on the influence of sex differences on the action of psychotropic drugs#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 324-331.
[12]	LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun. Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
[13]	GUO Xianzhong, LIN Rongfang, LIN Weiwei. Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
[14]	LI Jian, YANG Jinbo, WANG Yuzhu. Discussion on the format and content of new drug population pharmacokinetic study report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
[15]	ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian. Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.

Population pharmacokinetics of vancomycin in post-operative neurosurgical patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments